EXPOSURE TO HYPOXIA IN ANIMALS and humans is known to stimulate erythropoiesis that facilitates arterial oxygen delivery, thus partially restoring tissue oxygenation (21) . Hypoxic stimulation of erythropoietin production in the in vivo kidney can be mimicked in cultured erythropoietin-producing cell lines such as Hep3B (14) . This discovery led several investigators (1, 4, 13, 15) to a concept of a cellular oxygen-sensing mechanism, where cells may be able to detect reductions of oxygen level of their external milieu and respond by expressing specific genes, such as the erythropoietin gene, for survival during oxygen deprivation.
Several recent studies have revealed three important features of the cellular oxygen-sensing mechanism. First, besides erythropoietin, a variety of genes relating to hypoxia adaptation are induced at lowoxygen tensions, including genes encoding vascular growth factors, glycolytic enzymes, and glucose transporters in various cell types (10, 13) . Second, the cellular oxygen-level-sensing mechanism appears to rely on a heme protein, because reagents that modify heme, such as Co 2ϩ , can induce the response in the absence of hypoxia, whereas heme synthesis inhibitors were demonstrated to abolish the hypoxic response (15) . Third, in contrast to the diversities regarding hypoxia-sensitive genes and cell types, the induction of these genes appears to follow a common intracellular signal transduction pathway that is eventually mediated by a transcriptional factor, hypoxia inducible factor-1 (HIF-1) (13, 30) .
In the in vivo heart and cultured cardiac cells, both hypoxia and Co 2ϩ quickly induce mRNA for vascular endothelial growth factor (VEGF) (2, 8, 18, 24, 25, 27) , glucose transporter-1 (GLUT-1) (33, 38) , and heme oxygenase-1 (8, 23) , presumably by the same intracellular mechanism. These findings allow a speculation that the heart could adapt to oxygen deficiencies by activating the endogenous cellular oxygen-sensing mechanism. However, it remains to be elucidated whether activation of such an intracellular mechanism leads to functional improvement of cardiac contraction in hypoxia-reoxygenation in the beating heart.
Considering these factors, we undertook the present study to examine the effects of pretreating rats with a low concentration oral CoCl 2 on mechanical function of isolated crystalloid-perfused hearts in hypoxia-reoxygenation.
Pairs of the control and Co 2ϩ -treated rats were kept in separate cages for 6-7 wk in our animal facility. The rats had free access to food and water. Rats in the control group drank tap water, whereas rats in the Co 2ϩ group drank water containing 0.01% CoCl 2 . Body weight and water intake were measured twice a week.
Langendorff perfusion. The rats were anesthetized by intraperitoneal injection with 50 mg/kg pentobarbital sodium (Nembutal, Abbott Laboratories). Blood was then sampled from the tail vein, and hematocrit was measured with the use of the standard microcapillary method. After total heparinization (300 U/kg), the chest was opened, and the heart was excised and connected to a constant pressure (85 cmH 2 O) Langendorff perfusion system. The heart was perfused with 95% O 2 -5% CO 2 equilibrated Krebs-Henseleit bicarbonate buffer (KHB) solution containing (in mM) 120 NaCl, 25 NaHCO 3 , 4.7 KCl, 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 1.2 CaCl 2 , and 11 glucose at 37°C. A water-filled balloon was inserted into the left ventricle via the left atrium. The left ventricular (LV) pressure was measured with a pressure transducer (model P23 XL, Ohmeda) connected to the balloon and was continuously recorded on a thermal pen recorder (model WR3701, Graphtec). The end-diastolic pressure (EDP) was initially set to 8 mmHg by adjusting the volume of the balloon. In spontaneously beating isolated perfused hearts, perfusion with a hypoxic medium rapidly attenuated LV developed pressure (LVDP) and heart rate (HR), and spontaneous beating became undetectable during almost all the hypoxic period. In these hearts, cardiac contractions recovered close to the control level on reoxygenation. Therefore, using the electrical pacing, the heart was forced to beat as long as possible in hypoxia. A pair of platinum electrodes were placed on the atrium, and electrical pacing was conducted at 300 or 333 beats/min (depending on the spontaneous beating rate before cardiac pacing) with the use of an electric stimulator (model SEN3301, Nihon Kohden). Voltage of the pacing pulse was fixed to 150% of the initial pacing threshold determined during aerobic perfusion. We measured LVDP, EDP, and HR from the tracing of LV pressure. To assess the cardiac work, we calculated rate-pressure product (RPP ϭ LVDP ϫ HR). Coronary flow (CF) was determined by timed collections of coronary effluent that was subsequently normalized to the wet weight of the heart.
After the stabilization period for Ͼ1 h, the perfusion solution was switched to 95% N 2 -5% CO 2 equilibrated KHB solution (solution PO 2 Ͻ 30 mmHg). This hypoxic perfusion was continued for 60 min, followed by a perfusion with 95% O 2 -5% CO 2 equilibrated KHB solution (reoxygenation) for 60 min. Electrical pacing was discontinued during the reoxygenation period.
Tissue Co 2ϩ concentration. The hearts were excised from anesthetized and heparinized rats. The coronary artery was immediately perfused with cold saline to wash out blood. The ventricle was then isolated and freeze-clamped in liquid nitrogen. Myocardial Co 2ϩ concentration was analyzed by an independent research laboratory (Toray Research Center) with the use of an inductively coupled plasma mass analyzer (model SPQ 6500, Seiko Instruments).
Histological studies. The hearts were excised from anesthetized and heparinized rats. The coronary artery was perfused for 2 min with the HEPES buffer solution containing (in mM) 150 NaCl, 3.8 KCl, 1.0 KH 2 PO 4 , 1.2 MgSO 4 , 1.0 CaCl 2 , 10 glucose, and 10 HEPES; pH 7.4 at 37°C. The hearts were then perfused with either 10% formaldehyde or 1.25% gluteraldehyde at a constant perfusion pressure head of 85 cmH 2 O. The formaldehyde-fixed sample was stained with hematoxylin plus eosin, Elastica-Masson, phosphotungstic acid hematoxylin, and periodic acid-Schiff and subjected to light microscopic studies. The gluteraldehyde-fixed specimen was postfixed with osmium tetroxide, embedded in Epon, stained with lead citrate-uranyl acetate, and subjected to electron microscopic studies.
Cellular oxygen consumption. Single cardiomyocytes were isolated from the control and Co 2ϩ -treated rat hearts using collagenase (type II, Worthington) digestion method as described previously (34) and suspended in the HEPES buffer solution supplemented with 0.1% bovine serum albumin. An aliquot of 10 ml of the cell suspension was placed in an airtight measuring cuvette equipped with a Clark type oxygen electrode (model 17026, Instrumentation Laboratory). Circulating warm water regulated the temperature of the cuvette at 37°C. The cell suspension was vigorously stirred with the use of a magnetic stirrer. Time-dependent changes in cell suspension PO 2 were recorded every 3 s using MacLab (ADInstruments) system where the average rate of fall of PO 2 was calculated and converted to the oxygen consumption rate normalized to the number of normal rod-shaped cells (34) . We also determined the maximum rate of mitochondrial respiration in isolated cardiomyocytes after treatment with an uncoupler of oxidative phosphorylation, carbonyl cyanide m-chlorophenylhydrazone (CCCP).
Tissue glycogen concentration. Glycogen concentration of the LV free wall was determined by the enzymatic method developed by Brodal and Gehrken (3) . Briefly, the heart was excised from anesthetized and heparinized rats. The coronary artery was immediately perfused with cold saline to wash out blood. Small pieces of myocardial tissue (5-10 mg) were then sampled from the LV free wall, hydrolyzed, and neutralized. Tissue glycogen was enzymatically converted to glucose 6-phosphate that was finally oxidized to NADH and quantitated by the fluorometry at 340 nm (model UV260, Shimadzu).
RT-PCR. The hearts were excised from anesthetized and heparinized rats. The coronary artery was immediately perfused with cold saline, and the ventricle was isolated, frozen, and stored at Ϫ80°C. The total mRNAs were isolated with the use of QuickPrep mRNA Purification kit (Pharmacia Biotech). The concentration of the mRNAs were determined by spectrophotometry at 260 nm. The first strand cDNAs were synthesized in 20-l reaction solutions from 500 ng of total mRNAs using reverse transcriptase with oligodT primer (GIBCO-BRL). The primers for PCR were designed on the basis of the published mRNA sequences. To avoid amplification of the genomic DNA, each pair of the primers was derived from the coding regions intervened with introns. The sense and antisense primers, respectively, were composed of 5Ј-CGCATCTGCAATGGATGGTC-3Ј and 5Ј-TCTTCACCAC-CACAGGCTTCTG-3Ј for ribosomal protein L28 mRNA, 5Ј-ACCATGAACTTTCTGCTCTCTTGG-3Ј and 5Ј-TGCATAGT-GACGTTGCTCTCCGAC-3Ј for VEGF mRNA, 5Ј-GGCAAG-CTGTGCTTCATGTTCC-3Ј and 5Ј-GCTGAATAGGCTGCGT-TCTCTTG-3Ј and 5Ј-GAAAAGGATCACCCCTCCAATG-3Ј for aldolase-A mRNA and 5Ј-TCAACGAGCATCTTCGA-GAAGG-3Ј and 5Ј-TAGAGAAGCCAGCCACAGCAACAG-3Ј for GLUT-1 mRNA. L28 was used as a standard of the constitutive expression. All PCRs were performed in a final volume of 20 l containing dNTPs (0.2 mM), Taq polymerase (1 U), the primers (1 M), and cDNAs (0.5 l). The PCR products (5 l) were separated by a 3% Nusieve GTG agarose gel electrophoresis and visualized by Fas-3 CCD camera (Toyobo) after ethidium bromide staining. All of the PCR products were confirmed by DNA sequencing.
Statistics. Data are represented as means Ϯ SE. The differences between Co 2ϩ -treated and control rats for hemat-ocrit, body weight, heart weight, cellular oxygen consumption, and myocardial glycogen concentration were judged by the Student's unpaired t-test. Differences between Co 2ϩ -treated and control rats for cardiac mechanical functions were assessed by a two-way ANOVA followed by Scheffé's F-test. For all statistical tests, P Ͻ 0.05 was considered significant.
RESULTS

CoCl 2 effects on hematocrit.
Nineteen rats were treated with oral CoCl 2 for 43 days on average, whereas 18 rats were kept for the same time period as the control group. Net intake of CoCl 2 , calculated from water intake per day and CoCl 2 concentration in water (0.01%), slightly increased from ϳ4 to ϳ5 mg/day at the end of Co 2ϩ administration period, whereas CoCl 2 intake normalized to the body weight significantly decreased from ϳ20 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 (start) to ϳ10 mg ⅐ kg Ϫ1 ⅐ day Ϫ1 (end) due to approximately threefold increase in the body weight. Table 1 summarizes changes in hematocrit, body weight, and heart weight at the end of the Co 2ϩ administration period. Chronic oral administration of CoCl 2 significantly increased hematocrit without any effect on body weight or heart weight.
Cardiac contractile functions. All of the functional parameters measured during initial normoxic perfusion (baseline values) were similar in control and Co Figure 1 compares changes in LVDP between control and Co 2ϩ -pretreated hearts. During hypoxic perfusion, LVDP showed biphasic suppressions and remained low during reoxygenation. LVDP of the Co 2ϩ group heart was significantly higher than that of the control group heart at the end of hypoxic perfusion (196% at 65-70 min) and during reoxygenation (156% at 125-130 min). Figure 2 represents changes in HR. Severe bradycardia occurred immediately after the onset of hypoxic perfusion in both groups. However, HR gradually restored toward the baseline in the rest of hypoxic perfusion period. It is worth noting that severe arrhythmia developed and the heart stopped beating during hypoxic perfusion in 5 of 18 control hearts, whereas all of the hearts in the Co 2ϩ group sustained rhythmic contractions. Cardiac contractile work assessed by RPP most clearly indicates better tolerance of the Co 2ϩ group heart to hypoxia (Fig. 3) ; although significantly downregulated, RPP of the Co 2ϩ group heart was more than two times higher than the control heart throughout hypoxic period (267% at 65-70 min) and at almost all the measuring points in reoxygen- ation period (163% at 125-130 min). Better cardiac energy state in the Co 2ϩ group heart can be inferred from EDP (Fig. 4) . Although there were substantial rises in EDP during hypoxic and reoxygenation periods, peak EDP during hypoxic period and average EDP during reoxygenation period were significantly lower in the Co 2ϩ pretreated heart (72% at 65-70 min and 60% at 125-130 min), suggesting higher cellular ATP level. Figure 5 represents changes in CF. Hypoxic perfusion caused immediate vasodilatation, but CF gradually decreased during hypoxia, presumably due to hypercontracture that was reflected by the elevation of EDP. CF in the Co 2ϩ group heart was significantly higher at the end of hypoxia (127% at 65-70 min) and during reoxygenation period (118% at 125-130 min).
Tissue Co 2ϩ concentration. In two more rats given CoCl 2 for 45 and 42 days, the myocardial tissue Co 2ϩ concentrations were 0.57 and 0.63 g/g wet, respectively, and hematocrit increased to 52 and 50%, respectively. The body weight of the rats was the same (480 g).
Histological studies. Four more rats were subjected to the histological studies. Two rats were treated with oral CoCl 2 for 47 days, and their hematocrit levels rose to 52% and 54%, respectively. Neither light nor electron microscopic study indicated abnormalities, including inflammation, myocardial hypertrophy, degeneration and loss of myofilaments, or interstitial fibrosis, similar to the control hearts (n ϭ 2).
Cellular oxygen consumption. Cobalt may directly interfere with oxidation of fatty acids and pyruvate (36) . This might affect cellular energy metabolism in hypoxia-reoxygenation. We examined the metabolic effect of chronic oral CoCl 2 administration in two ways; mitochondrial respiration and tissue glycogen concentration. Fourteen more rats (seven control and seven Co 2ϩ treated) were subjected to the measurement of cellular oxygen consumption. At -treated rats of this particular experiment were 44% (SE ϭ 0, n ϭ 7) and 50 Ϯ 0.5% (n ϭ 7), respectively.
Tissue glycogen concentration. Suppression of glycolytic metabolism by Co 2ϩ , if any, may raise tissue glycogen concentration (28) . Fourteen more rats (seven control and seven Co 2ϩ treated) were subjected to this study. Tissue glycogen concentration was the same in the control (26.0 Ϯ 3.1 mol glucose/g wet, n ϭ 7) and the Co 2ϩ -treated rat hearts (31.4 Ϯ 3.1 mol glucose/g wet, n ϭ 7, p ϭ 0.24). The hematocrit values of the control and Co 2ϩ -treated rats of this particular experiment were 45 Ϯ 0.5 and 52 Ϯ 0.7%, respectively.
RT-PCR. Eight (four control and four Co 2ϩ treated) rat hearts were used. Figure 6 represents semiquantitative assessment of VEGF, aldolase-A, and GLUT-1 mRNAs. On days 7 and 14 of oral CoCl 2 administration, significant inductions of VEGF, aldolase-A, and GLUT-1 mRNAs were observed, whereas levels of these mRNAs were comparable to the control heart on day 30. 
DISCUSSION
Activation of cellular oxygen-sensing mechanism in vivo by a low-concentration chronic oral CoCl 2 .
Erythropoiesis is known to be greatly stimulated by tissue hypoxia caused by hypoxemia, anemia, or hemorrhage (21) . Glycoprotein hormone erythropoietin is the primary regulator of erythropoiesis. It has been known for a long time that cobalt increases erythropoietin production in vitro (12) and in vivo (20) in normoxia. Cobalt was once given to human patients for the treatment of anemia (6), although the mechanism for enhanced erythropoietin production by Co 2ϩ had been unknown.
Recently, Goldberg et al. (14) demonstrated in the human hepatoma cell lines, Hep3B and HepG2, that production of erythropoietin mRNA was stimulated 6-to 12-fold in response to Co 2ϩ in the absence of hypoxia. It was subsequently demonstrated that carbon monoxide blocked erythropoietin production in hypoxia, and inhibition of heme synthesis abolished the erythropoietin response to CoCl 2 . These lines of evidence suggest an involvement of a heme protein in the intracellular signal transduction. Goldberg et al. (15) postulated that Co 2ϩ might substitute for Fe 2ϩ of the putative intracellular heme protein oxygen sensor, thus inhibiting binding of molecular oxygen to the heme, and fix the oxygen sensor in the deoxy form.
Expression of erythropoietin gene is regulated by a transcriptional factor HIF-1 that binds to the enhancer region of the erythropoietin gene (10, 29, 30 ). Therefore, the alternative hypothesis for activation of the oxygen-sensing mechanism by Co 2ϩ is that Co 2ϩ might stabilize HIF-1 by interfering with the action of oxygen in producing reactive oxygen species (the redox reaction) (1, 4, 9, 16 ).
In the present study, in accordance with previous observations in animals (20) and humans (6), chronic oral administration of CoCl 2 induced polycythemia without an effect on body or heart weight. Although we did not measure the blood erythropoietin level, these findings strongly suggest an in vivo activation of the cellular oxygen-sensing mechanism.
Excess amounts of Co 2ϩ is cardiotoxic in humans and experimental animals, known as the cobalt cardiomyopathy (28) . The mechanism appears to involve suppression of the citric acid cycle, which is reflected by depression of mitochondrial oxygen uptake (36) . Therefore, optimization of Co 2ϩ administration protocol is of critical importance in this study. In fact, the rats lost considerable weight if they were given water containing Ͼ0.02% CoCl 2 . One rat that drank 0.01% CoCl 2 water for 45 days developed pericardial effusion, a cardiac lesion characteristic to the cobalt cardiomyopathy (28) . However, all the Co 2ϩ -treated rats participated in the cardiac function study showed normal weight gain and normal wet weight of the heart (Table  1) . Separate histological studies excluded possibility of degeneration, hypertrophy, or inflammatory changes in the myocardium. Furthermore, oxygen uptake of isolated quiescent single cardiomyocytes, even when maximally stimulated, was normal, suggesting that metabolic substrates utilization was not disturbed. Concentration of tissue Co 2ϩ in the present Co 2ϩ -treated rat hearts was ϳ0.6 g/g wet. The value is significantly higher compared with normal human hearts (0.01ϳ0.04 g/g dry, Ref. 5) , but it appears to be significantly lower than that found in the cobalt cardiomyopathy (0.7-5.5 g/g dry, average 3.3 g/g dry, Ref. 5). Collectively, we conclude that the present method of cobalt administration was adequate to activate the cellular oxygen-sensing mechanism without significant damage to myocardium.
Improvement of cardiac mechanical function during hypoxia-reoxygenation in Co
2ϩ -treated rat hearts. In hypoxia and reoxygenation, crystalloid-perfused hearts isolated from the Co 2ϩ -pretreated rats showed superior contractile performance compared with control hearts. Thus the Co 2ϩ -pretreated rat heart can better adapt to reduced oxygen supply. In the perfused heart preparation, EDP and RPP reflect cellular ATP level and energy consumption by cardiac contraction, respectively. The present findings that the heart isolated from the Co 2ϩ -pretreated rat exhibited a lower increase in EDP despite higher RPP in hypoxia-reoxygenation may imply that ATP production in the Co 2ϩ -pretreated rat heart was better maintained in hypoxia than the control heart. Several effects of Co 2ϩ may potentially account for the observed hypoxic tolerance.
Because excess Co 2ϩ interferes with oxidation of pyruvate to acetyl CoA (36), nonutilized pyruvate may proceed to glycogen, thus increasing cellular glycogen stores (28) . In the face of severe suppression of oxidative ATP production in hypoxia, the already-increased glycogen stores could continuously supply some amounts of ATP by anaerobic glycolysis so that the cellular energy state would not be severely impaired. Nevertheless, in the present study, an increase in myocardial tissue glycogen in Co 2ϩ -treated rats was insignificant to allow for such an account.
If erythropoiesis as observed in the present study occurred secondary to activation of the cellular oxygensensing mechanism by oral CoCl 2 , it is natural to postulate that not only erythropoietin gene expression in the kidney but also other hypoxia-sensitive genes in other organs would be upregulated, because hypoxia should have activated the common intracellular mediator HIF-1 that operates at physiological oxygen concentrations (19, 22, 35, 39) . In the heart, we therefore expected that activation of the oxygen-sensing mechanism by Co 2ϩ would stimulate expression of genes that are important for hypoxic adaptations. Such molecular adaptation to hypoxia might eventually lead to functional improvement of cardiac contractile activity during hypoxia and reoxygenation.
The present study demonstrates in vivo induction of VEGF mRNA in cardiac tissue (Fig. 6 ) as shown in the previous studies (24, 25, 27) . VEGF is a potent angiogenic factor and upregulation of VEGF may facilitate tissue perfusion and oxygenation in hypoxia, an important adaptation to hypoxia. It has been reported that Co 2ϩ induces various glycolytic enzymes (7, 11, 26, 31) along with glucose transporters (38) . The present study also demonstrated in vivo inductions of aldolase-A and GLUT-1 mRNAs in Co 2ϩ -treated cardiac tissue (Fig.  6 ). These findings suggest that the reserve for glycolytic energy production was higher in Co 2ϩ -pretreated rat hearts. It is then presumable that the augmented glycolytic ATP flux would decelerate loss of high-energy phosphate pools in hypoxia.
In the cobalt-treated rats, hematocrit started to rise from day 30 and reached a plateau after day 40. Cardiac mechanical functions were subsequently determined on day 43, on average. Increases in levels of VEGF, GLUT-1, and aldolase-A mRNAs preceded the increase in hematocrit; they were detectable as early as on days 7 and 14 and leveled off on day 30. Because time course of the regulatory changes in genes and proteins induced by hypoxia and/or cobalt has not been precisely defined in vivo, it is difficult to definitely relate these genetic changes to the observed changes in cardiac contractility. However, previous reports suggest that in vivo effects of activation of hypoxia-related genes may persist for a prolonged time period. Harik et al. (17) demonstrated that exposure of rats to hypobaric hypoxia for 3 wk significantly increased GLUT-1 in cerebral microvessels, whereas it remained elevated even 3 wk after normoxic recovery at which GLUT-1 mRNA was returned to the control level. Similarly, Xie et al. (37) observed strong immunohistochemical stainings against basic fibroblast growth factor and VEGF near capillaries of rat hearts that underwent a transient ischemia (3 min) 30 days previously. Moreover, a half-life of 20 days has been reported for rat muscle aldolase (32) . Together, it is possible that, among many hypoxia-related genes, at least three genes examined in the present study may well contribute to the hypoxic resistance of cardiac contractile functions determined after 43 days (average) of oral cobalt administration.
The heart can adapt to reduced oxygen supply in various ways, including coronary vasodilation, downregulation of cellular oxygen demands, ischemic preconditioning, stimulation of anaerobic glycolysis (Pasteur effect), neovascularization, and increased myocardial myoglobin concentration. In addition, activation of the endogenous oxygen-sensing mechanism and subsequent induction of genes that are beneficial for hypoxic adaptation should be an effective strategy of the heart to adapt to hypoxia.
